Chimeric RNAs and their implication in prostate cancer  

作　　者：Hui Li Qiong Wang 

机构地区：[1]Department of Pathology,School of Medicine,University of Virginia,Charlottesville,VA 22908,USA [2]Department of Urology,Nanfang Hospital,Southern Medical University,Guangzhou,Guangdong 510515,China

出　　处：《Cancer Pathogenesis and Therapy》2023年第3期216-219,共4页癌症发生与治疗（英文）

基　　金：supported by the China Scholarship Council(No.201906380075);Guangdong Province Natural Science Foundation(No.2023A1515011905).

摘　　要：Introduction.Specific gene fusions and their resultant fusion products,including chimeric ribonucleic acid(RNA)and protein,have long served as ideal tumor diagnostic markers and therapeutic targets.Despite this,only a few systematic studies on chimeric RNAs have been conducted in prostate cancer(PCa).In this study,we summarize the discovery pipeline,formation mechanisms,method of action,and future perspectives of chimeric RNAs.We aim to provide a viewpoint for exploring novel targets for diagnosing or treating PCa.

关 键 词：Prostate cancer Chimeric RNAs TRANS-SPLICING Cis-SAGe 

分 类 号：R737.25[医药卫生—肿瘤]